Kickboxing and Cognition in Parkinson's Disease Save

Date Added
July 22nd, 2016
PRO Number
Pro00054295
Researcher
Vanessa Hinson

Silhouette
Keywords
Exercise, Memory Loss, Parkinsons
Summary

You are invited to volunteer for a research study if you have been diagnosed with Parkinson's Disease (PD) Stage 1-3.

This study will examine whether a kickboxing regime called "Rock Steady Boxing" helps improve cognitive dysfunction (thinking problems) in subjects with Parkinson's disease. "Rock Steady Boxing" is a fairly recent intervention for PD exercise rehabilitation.This program incorporates elements of aerobic exercise, with range of motion, visual spatial awareness, endurance, speed, agility, voice strengthening, and cognitive tasks. Your are eligible to participate if you plan to undergo Rock Steady Boxing as part of your own personal health plan, or you have indicated that you exercise regularly, but you do not intend to start Rock Steady Boxing.

Institution
MUSC
Recruitment Contact
Amy Delambo
843-792 5543
delambo@musc.edu

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease Save

Date Added
September 8th, 2015
PRO Number
Pro00044560
Researcher
David Clark

Silhouette
Keywords
Alzheimers, Memory Loss
Summary

This study will be conducted in subjects with early AD, including subjects with mild cognitive impairment (MCI) due to AD and a subset of mild AD.

The purpose of this study is to find out whether (study drug) has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer's Disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

The subject will have the option of participating in four sub-studies: DNA, positron emission tomography (PET), magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) or the Long Term Extension study (LTE).

Study duration for each subject participating in the placebo-controlled period only will be approximately 102 weeks (up to an 8 week Screening Period, 76 weeks of placebo or aducanumab dosing, and 18 weeks of follow-up).

For subjects who enter the optional LTE, the total duration will be approximately 206 weeks or 47 months (up to an 8 week Screening Period, 76 weeks of placebo or aducanumab dosing, 4 weeks of follow-up, 100 weeks of dose-blind aducanumab dosing, and 18 weeks of follow-up).

Institution
MUSC
Recruitment Contact
Michele DeCandio
2-9016
decandio@musc.edu

The MIND Study: MR Imaging of Neurodegeneration Save

Date Added
September 18th, 2013
PRO Number
Pro00028302
Researcher
Andreana Benitez

Silhouette
Keywords
Aging, Alzheimers, Brain, Dementia, Geriatrics, Healthy Volunteer Studies, Memory Loss
Summary

This is a study of brain aging and Mild Cognitive Impairment (MCI). In this study, we use non-invasive brain MRI techniques and tests of memory and other thinking skills to improve the detection of brain diseases of aging at the very earliest stages. A fasting blood draw will also be performed to help clarify the contribution of blood sugar and cholesterol to brain aging. We are primarily recruiting 80 individuals ages 65-85 who have been diagnosed with Mild Cognitive Impairment (MCI) by their healthcare provider. We are also recruiting individuals ages 65-85 who are cognitively healthy and do not have any significant or unstable medical conditions. This study is sponsored by the NIH and is conducted at MUSC.

If you are interested in this study, please contact us by phone or through: http://bit.ly/MIND-study

Institution
MUSC
Recruitment Contact
Anne Sorrell
(843) 876-2475
sorrella@musc.edu

A Multi-Center Randomized Placebo-Contolled Clinical Trial Study of Citalopram for the treatment of Agitation in Alzheimer's Disease (CITAD) Save

Date Added
October 5th, 2009
IRB Number
18350
Researcher
Jacobo Mintzer

Silhouette
Keywords
Aging, Alzheimers, Anxiety, Brain, Dementia, Geriatrics, Memory Loss, Mental Health
Summary

This study is designed to examine the effects and safety of citalopram in patients with Alzheimer's disease experiencing agitation or emotional disturbance. This study is 9 weeks long. In order to participate in this study, you must be at least 45 years old, have Alzheimer's disease and experience agitation. Participants cannot have depression. Participants may stay on approved memory medications for Alzheimer's disease.

Institution
MUSC
Recruitment Contact
Marie Corbin
843-740-1592
corbinm@musc.edu

Change_preferences

-- OR --

Create_login